Abstract
Primary central nervous system lymphoma is a rare aggressive disease that largely affects elderly patients and is associated with poor prognosis. The optimal treatment approach is not yet defined and it consists of induction and consolidation phases. The combination of high-dose (HD) methotrexate-based chemotherapy followed by whole-brain radiotherapy (WBRT) prolongs the median progression-free survival (PFS) and overall survival 2- to 3-fold as compared to WBRT alone but is associated with significant delayed neurotoxicity. Alternative strategies are being investigated in order to improve disease outcomes and spare patients the neurocognitive side effects. These include reduced-dose WBRT, non-myeloablative HD chemotherapy, or HD chemotherapy with autologous stem cell transplantation (HDC/ASCT). There are no randomized studies that compare all these consolidation regimens head to head but recently HDC/ASCT has been evaluated versus WBRT in prospective randomized studies. These studies proved that WBRT and HDC/ASCT yield similar 2-year PFS with preserved or improved cognitive function after HDC/ASCT. Yet, the proportion of patients treated with such intensive consolidation is low, both in real life and in specialized centers, leaving many unsettled issues. This review is appraising current dilemmas related to the choice of consolidating therapeutic modalities, their associated acute and delayed toxicity, and future prospects for alternative approaches in the elderly.
References
1.
Swerdlow
SH
, Campo
E
, Pileri
SA
, Harris
NL
, Stein
H
, Siebert
R
, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms
. Blood
. 2016
;127
(20
):2375
–90
. .2.
Daneman
R
, Prat
A
. The blood-brain barrier
. Cold Spring Harb Perspect Biol
. 2015
;7
(1
):a020412
. .3.
Muldoon
LL
, Soussain
C
, Jahnke
K
, Johanson
C
, Siegal
T
, Smith
QR
, et al. Chemotherapy delivery issues in central nervous system malignancy: a reality check
. J Clin Oncol
. 2007
;25
(16
):2295
–305
. .4.
Deckert
M
, Engert
A
, Brück
W
, Ferreri
AJ
, Finke
J
, Illerhaus
G
, et al. Modern concepts in the biology, diagnosis, differential diagnosis and treatment of primary central nervous system lymphoma
. Leukemia
. 2011
;25
(12
):1797
–807
. .5.
Grommes
C
, Rubenstein
JL
, DeAngelis
LM
, Ferreri
AJM
, Batchelor
TT
. Comprehensive approach to diagnosis and treatment of newly diagnosed primary CNS lymphoma
. Neuro Oncol
. 2019
;21
(3
):296
–305
. .6.
Fox
CP
, Phillips
EH
, Smith
J
, Linton
K
, Gallop-Evans
E
, Hemmaway
C
, et al. Guidelines for the diagnosis and management of primary central nervous system diffuse large B-cell lymphoma
. Br J Haematol
. 2019
;184
(3
):348
–63
. .7.
Reni
M
, Mazza
E
, Foppoli
M
, Ferreri
AJ
. Primary central nervous system lymphomas: salvage treatment after failure to high-dose methotrexate
. Cancer Lett
. 2007
;258
(2
):165
–70
. .8.
Abrey
LE
, Ben-Porat
L
, Panageas
KS
, Yahalom
J
, Berkey
B
, Curran
W
, et al. Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model
. J Clin Oncol
. 2006
;24
(36
):5711
–5
. .9.
Ferreri
AJ
, Blay
JY
, Reni
M
, Pasini
F
, Spina
M
, Ambrosetti
A
, et al. Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience
. J Clin Oncol
. 2003
;21
(2
):266
–72
. .10.
Mendez
JS
, Ostrom
QT
, Gittleman
H
, Kruchko
C
, DeAngelis
LM
, Barnholtz-Sloan
JS
, et al. The elderly left behind-changes in survival trends of primary central nervous system lymphoma over the past 4 decades
. Neuro Oncol
. 2018
;20
(5
):687
–94
. .11.
Siegal
T
, Bairey
O
. Primary CNS lymphoma in the elderly: the challenge
. Acta Haematol
. 2019
;141
(3
):138
–45
. .12.
DeAngelis
LM
, Yahalom
J
, Thaler
HT
, Kher
U
. Combined modality therapy for primary CNS lymphoma
. J Clin Oncol
. 1992
;10
(4
):635
–43
. .13.
Nelson
DF
, Martz
KL
, Bonner
H
, Nelson
JS
, Newall
J
, Kerman
HD
, et al. Non-Hodgkin’s lymphoma of the brain: can high dose, large volume radiation therapy improve survival? Report on a prospective trial by the Radiation Therapy Oncology Group (RTOG): RTOG 8315
. Int J Radiat Oncol Biol Phys
. 1992
;23
(1
):9
–17
. .14.
Gavrilovic
IT
, Hormigo
A
, Yahalom
J
, DeAngelis
LM
, Abrey
LE
. Long-term follow-up of high-dose methotrexate-based therapy with and without whole brain irradiation for newly diagnosed primary CNS lymphoma
. J Clin Oncol
. 2006
;24
(28
):4570
–4
. .15.
Thiel
E
, Korfel
A
, Martus
P
, Kanz
L
, Griesinger
F
, Rauch
M
, et al. High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial
. Lancet Oncol
. 2010
;11
(11
):1036
–47
. .16.
Ferreri
AJ
, Illerhaus
G
. The role of autologous stem cell transplantation in primary central nervous system lymphoma
. Blood
. 2016
;127
(13
):1642
–9
. .17.
Bairey
O
, Siegal
T
. The possible role of maintenance treatment for primary central nervous system lymphoma
. Blood Rev
. 2018 Sep
;32
(5
):378
–86
.18.
Bromberg
JEC
, Issa
S
, Bakunina
K
, Minnema
MC
, Seute
T
, Durian
M
, et al. Rituximab in patients with primary CNS lymphoma (HOVON 105/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study
. Lancet Oncol
. 2019
;20
(2
):216
–28
. .19.
Schmitt
AM
, Herbrand
AK
, Fox
CP
, Bakunina
K
, Bromberg
JEC
, Cwynarski
K
, et al. Rituximab in primary central nervous system lymphoma-A systematic review and meta-analysis
. Hematol Oncol
. 2019
;37
(5
):548
–57
. .20.
Glass
J
, Won
M
, Schultz
CJ
, Brat
D
, Bartlett
NL
, Suh
JH
, et al. Phase I and II study of induction chemotherapy with methotrexate, rituximab, and temozolomide, followed by whole-brain radiotherapy and postirradiation temozolomide for primary CNS lymphoma: NRG oncology RTOG 0227
. J Clin Oncol
. 2016
;34
(14
):1620
–5
. .21.
Rubenstein
JL
, Hsi
ED
, Johnson
JL
, Jung
SH
, Nakashima
MO
, Grant
B
, et al. Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202)
. J Clin Oncol
. 2013
;31
(25
):3061
–8
. .22.
DeAngelis
LM
, Seiferheld
W
, Schold
SC
, Fisher
B
, Schultz
CJ
; Radiation Therapy Oncology Group S
. Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93-10
. J Clin Oncol
. 2002
;20
(24
):4643
–8
. .23.
Morris
PG
, Correa
DD
, Yahalom
J
, Raizer
JJ
, Schiff
D
, Grant
B
, et al. Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcome
. J Clin Oncol
. 2013
;31
(31
):3971
–9
. .24.
Omuro
A
, Correa
DD
, DeAngelis
LM
, Moskowitz
CH
, Matasar
MJ
, Kaley
TJ
, et al. R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma
. Blood
. 2015
;125
(9
):1403
–10
. .25.
Ferreri
AJ
, Cwynarski
K
, Pulczynski
E
, Ponzoni
M
, Deckert
M
, Politi
LS
, et al. Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial
. Lancet Haematol
. 2016
;3
(5
):e217
–27
. .26.
Ferreri
AJM
, Cwynarski
K
, Pulczynski
E
, Fox
CP
, Schorb
E
, La Rosée
P
, et al. Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial
. Lancet Haematol
. 2017
;4
(11
):e510
–23
. .27.
Correa
DD
, Maron
L
, Harder
H
, Klein
M
, Armstrong
CL
, Calabrese
P
, et al. Cognitive functions in primary central nervous system lymphoma: literature review and assessment guidelines
. Ann Oncol
. 2007
;18
(7
):1145
–51
. .28.
Correa
DD
, Shi
W
, Abrey
LE
, Deangelis
LM
, Omuro
AM
, Deutsch
MB
, et al. Cognitive functions in primary CNS lymphoma after single or combined modality regimens
. Neuro-oncology
. 2012
;14
(1
):101
–8
. .29.
Omuro
A
, MP
, DeAngelis
LM
, Karrison
T
, Bovi J
A
, Rosenblum
M
, et al. Randomized phase II study of rituximab, methotrexate (MTX), procarbazine, vincristine, and cytarabine (R-MPV-A) with and without low-dose whole-brain radiotherapy (LD-WBRT) for newly diagnosed primary CNS lymphoma (PCNSL)
. J Clin Oncol
. 2020
;38
(Suppl 15
).30.
Batchelor
T
, Sharmila
G
, Ruppert
AS
, Bartlett
NL
, Hsi
ED
, Cheson
BD
, et al. Myeloablative versus non-myeloablative consolidative chemotherapy for newly diagnosed primary central nervous system lymphoma: results of induction therapy in Alliance 51101
. J Clin Oncol
. 2020
;38
(Suppl 15
).31.
Houillier
C
, Taillandier
L
, Dureau
S
, Lamy
T
, Laadhari
M
, Chinot
O
, et al. Radiotherapy or autologous stem-cell transplantation for primary CNS lymphoma in patients 60 years of age and younger: results of the intergroup ANOCEF-GOELAMS randomized phase II PRECIS study
. J Clin Oncol
. 2019
;37
(10
):823
–33
. .32.
Hoang-Xuan
K
, Bessell
E
, Bromberg
J
, Hottinger
AF
, Preusser
M
, Rudà
R
, et al. Diagnosis and treatment of primary CNS lymphoma in immunocompetent patients: guidelines from the European Association for Neuro-Oncology
. Lancet Oncol
. 2015
;16
(7
):e322
–32
. .33.
Schlegel
U
, Korfel
A
. Is whole-brain radiotherapy still a standard treatment for primary central nervous system lymphomas?
Curr Opin Neurol
. 2018
;31
(6
):733
–9
. .34.
Abrey
LE
, DeAngelis
LM
, Yahalom
J
. Long-term survival in primary CNS lymphoma
. J Clin Oncol
. 1998
;16
(3
):859
–63
. .35.
Lai
R
, Abrey
LE
, Rosenblum
MK
, DeAngelis
LM
. Treatment-induced leukoencephalopathy in primary CNS lymphoma: a clinical and autopsy study
. Neurology
. 2004
;62
(3
):451
–6
. .36.
Omuro
AM
, Ben-Porat
LS
, Panageas
KS
, Kim
AK
, Correa
DD
, Yahalom
J
, et al. Delayed neurotoxicity in primary central nervous system lymphoma
. Arch Neurol
. 2005
;62
(10
):1595
–600
. .37.
Fisher
B
, Seiferheld
W
, Schultz
C
, DeAngelis
L
, Nelson
D
, Schold
SC
, et al. Secondary analysis of Radiation Therapy Oncology Group study (RTOG) 9310: an intergroup phase II combined modality treatment of primary central nervous system lymphoma
. J Neurooncol
. 2005
;74
(2
):201
–5
. .38.
Houillier
C
, Ghesquières
H
, Chabrot
C
, Soussain
C
, Ahle
G
, Choquet
S
, et al. Rituximab, methotrexate, procarbazine, vincristine and intensified cytarabine consolidation for primary central nervous system lymphoma (PCNSL) in the elderly: a LOC network study
. J Neurooncol
. 2017
;133
(2
):315
–20
. .39.
Birsen
R
, Willems
L
, Pallud
J
, Blanc
E
, Burroni
B
, Legoff
M
, et al. Efficacy and safety of high-dose etoposide cytarabine as consolidation following rituximab methotrexate temozolomide induction in newly diagnosed primary central nervous system lymphoma in immunocompetent patients
. Haematologica
. 2018
;103
(7
):e296
–9
. .40.
Abrey
LE
, Moskowitz
CH
, Mason
WP
, Crump
M
, Stewart
D
, Forsyth
P
, et al. Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis
. J Clin Oncol
. 2003
;21
(22
):4151
–6
. .41.
Illerhaus
G
, Marks
R
, Ihorst
G
, Guttenberger
R
, Ostertag
C
, Derigs
G
, et al. High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma
. J Clin Oncol
. 2006
;24
(24
):3865
–70
. .42.
Soussain
C
, Suzan
F
, Hoang-Xuan
K
, Cassoux
N
, Levy
V
, Azar
N
, et al. Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma
. J Clin Oncol
. 2001
;19
(3
):742
–9
. .43.
Duarte
RF
, Labopin
M
, Bader
P
, Basak
GW
, Bonini
C
, Chabannon
C
, et al. Indications for haematopoietic stem cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2019
. Bone Marrow Transplant
. 2019
;54
(10
):1525
–52
. .44.
Illerhaus
G
, Kasenda
B
, Ihorst
G
, Egerer
G
, Lamprecht
M
, Keller
U
, et al. High-dose chemotherapy with autologous haemopoietic stem cell transplantation for newly diagnosed primary CNS lymphoma: a prospective, single-arm, phase 2 trial
. Lancet Haematol
. 2016
;3
(8
):e388
–97
. .45.
Kassam
S
, Chernucha
E
, O’Neill
A
, Hemmaway
C
, Cummins
T
, Montoto
S
, et al. High-dose chemotherapy and autologous stem cell transplantation for primary central nervous system lymphoma: a multi-centre retrospective analysis from the United Kingdom
. Bone Marrow Transplant
. 2017
;52
(9
):1268
–72
. .46.
Sanders
S
, Chua
N
, Larouche
JF
, Owen
C
, Shafey
M
, Stewart
DA
. Outcomes of consecutively diagnosed primary central nervous system lymphoma patients using the alberta lymphoma clinical practice guideline incorporating thiotepa-busulfan conditioning for transplantation-eligible patients
. Biol Blood Marrow Transplant
. 2019
;25
(8
):1505
–10
. .47.
Schorb
E
, Kasenda
B
, Atta
J
, Kaun
S
, Morgner
A
, Hess
G
, et al. Prognosis of patients with primary central nervous system lymphoma after high-dose chemotherapy followed by autologous stem cell transplantation
. Haematologica
. 2013
;98
(5
):765
–70
. .48.
DeFilipp
Z
, Li
S
, El-Jawahri
A
, Armand
P
, Nayak
L
, Wang
N
, et al. High-dose chemotherapy with thiotepa, busulfan, and cyclophosphamide and autologous stem cell transplantation for patients with primary central nervous system lymphoma in first complete remission
. Cancer
. 2017
;123
(16
):3073
–9
. .49.
Hyung
J
, Hong
JY
, Yoon
DH
, Kim
S
, Park
JS
, Park
CS
, et al. Thiotepa, busulfan, and cyclophosphamide or busulfan, cyclophosphamide, and etoposide high-dose chemotherapy followed by autologous stem cell transplantation for consolidation of primary central nervous system lymphoma
. Ann Hematol
. 2019
;98
(7
):1657
–64
. .50.
Omuro
A
, Chinot
O
, Taillandier
L
, Ghesquieres
H
, Soussain
C
, Delwail
V
, et al. Methotrexate and temozolomide versus methotrexate, procarbazine, vincristine, and cytarabine for primary CNS lymphoma in an elderly population: an intergroup ANOCEF-GOELAMS randomised phase 2 trial
. Lancet Haematol
. 2015
;2
(6
):e251
–9
. .51.
Schorb
E
, Finke
J
, Ihorst
G
, Kasenda
B
, Fricker
H
, Illerhaus
G
. Age-adjusted high-dose chemotherapy and autologous stem cell transplant in elderly and fit primary CNS lymphoma patients
. BMC Cancer
. 2019
;19
(1
):287
. .52.
Houillier
C
, Soussain
C
, Ghesquières
H
, Soubeyran
P
, Chinot
O
, Taillandier
L
, et al. Management and outcome of primary CNS lymphoma in the modern era: an LOC network study
. Neurology
. 2020
;94
(10
):e1027
–39
. .53.
Schorb
E
, Fox
CP
, Kasenda
B
, Linton
K
, Martinez-Calle
N
, Calimeri
T
, et al. Induction therapy with the MATRix regimen in patients with newly diagnosed primary diffuse large B-cell lymphoma of the central nervous system: an international study of feasibility and efficacy in routine clinical practice
. Br J Haematol
. 2020 Jun
;185
(5
):879
–87
.54.
Martinez-Calle
N
, Poynton
E
, Alchawaf
A
, Kassam
S
, Horan
M
, Rafferty
M
, et al. Outcomes of older patients with primary central nervous system lymphoma treated in routine clinical practice in the UK: methotrexate dose intensity correlates with response and survival
. Br J Haematol
. 2020 Aug
;190
(3
):394
–404
.55.
Abrey
LE
, Batchelor
TT
, Ferreri
AJ
, Gospodarowicz
M
, Pulczynski
EJ
, Zucca
E
, et al. International Primary CNSLCG: report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma
. J Clin Oncol
. 2005
;23
:5034
–43
.56.
Miyakita
Y
, Ohno
M
, Takahashi
M
, Kurihara
H
, Katai
H
, Narita
Y
. Usefulness of carbon-11-labeled methionine positron-emission tomography for assessing the treatment response of primary central nervous system lymphoma
. Jpn J Clin Oncol
. 2020
;50
(5
):512
–8
. .57.
Duarte
RF
, Sanchez-Ortega
I
. HSCT in elderly patients
. In: Carreras
E
, Dufour
C
, Mohty
M
, Kroger
N
, editors. The EBMT handbook: hematopoietic stem cell transplantation and cellular therapies
. Cham
; 2019
. p. 499
–503
.58.
Schorb
E
, Fox
CP
, Fritsch
K
, Isbell
L
, Neubauer
A
, Tzalavras
A
, et al. High-dose thiotepa-based chemotherapy with autologous stem cell support in elderly patients with primary central nervous system lymphoma: a European retrospective study
. Bone Marrow Transplant
. 2017
;52
(8
):1113
–9
. .59.
Colombat
P
, Lemevel
A
, Bertrand
P
, Delwail
V
, Rachieru
P
, Brion
A
, et al. High-dose chemotherapy with autologous stem cell transplantation as first-line therapy for primary CNS lymphoma in patients younger than 60 years: a multicenter phase II study of the GOELAMS group
. Bone Marrow Transplant
. 2006
;38
(6
):417
–20
. .60.
Wiebe
VJ
, Smith
BR
, DeGregorio
MW
, Rappeport
JM
. Pharmacology of agents used in bone marrow transplant conditioning regimens
. Crit Rev Oncol Hematol
. 1992
;13
(3
):241
–70
. .61.
Makale
MT
, McDonald
CR
, Hattangadi-Gluth
JA
, Kesari
S
. Mechanisms of radiotherapy-associated cognitive disability in patients with brain tumours
. Nat Rev Neurol
. 2017
;13
(1
):52
–64
. .62.
Pazzaglia
S
, Briganti
G
, Mancuso
M
, Saran
A
. Neurocognitive decline following radiotherapy: mechanisms and therapeutic implications
. Cancers
. 2020
;12
(1
):146
. .63.
Cascella
M
, Di Napoli
R
, Carbone
D
, Cuomo
GF
, Bimonte
S
, Muzio
MR
. Chemotherapy-related cognitive impairment: mechanisms, clinical features and research perspectives
. Recenti Prog Med
. 2018
;109
(11
):523
–30
. .64.
Walczak
P
, Janowski
M
. Chemobrain as a product of growing success in chemotherapy: focus on glia as both a victim and a cure
. Neuropsychiatry
. 2019
;9
(1
):2207
–16
. .65.
Berlin
C
, Lange
K
, Lekaye
HC
, Hopland
K
, Phillips
S
, Piao
J
, et al. Long-term clinically relevant rodent model of methotrexate-induced cognitive impairment
. Neuro Oncol
. 2020 Aug 17
;22
(8
):1126
–37
.66.
Bhatia
S
, Robison
LL
, Francisco
L
, Carter
A
, Liu
Y
, Grant
M
, et al. Late mortality in survivors of autologous hematopoietic-cell transplantation: report from the Bone Marrow Transplant Survivor Study
. Blood
. 2005
;105
(11
):4215
–22
. .67.
Kelly
DL
, Buchbinder
D
, Duarte
RF
, Auletta
JJ
, Bhatt
N
, Byrne
M
, et al. Neurocognitive dysfunction in hematopoietic cell transplant recipients: expert review from the late effects and Quality of Life Working Committee of the Center for international blood and marrow transplant research and complications and Quality of Life Working Party of the European Society for blood and marrow transplantation
. Biol Blood Marrow Transplant
. 2018
;24
(2
):228
–41
. .68.
Buchbinder
D
, Kelly
DL
, Duarte
RF
, Auletta
JJ
, Bhatt
N
, Byrne
M
, et al. Neurocognitive dysfunction in hematopoietic cell transplant recipients: expert review from the late effects and Quality of Life Working Committee of the CIBMTR and complications and Quality of Life Working Party of the EBMT
. Bone Marrow Transplant
. 2018
;53
(5
):535
–55
. .69.
Correa
DD
, Braun
E
, Kryza-Lacombe
M
, Ho
KW
, Reiner
AS
, Panageas
KS
, et al. Longitudinal cognitive assessment in patients with primary CNS lymphoma treated with induction chemotherapy followed by reduced-dose whole-brain radiotherapy or autologous stem cell transplantation
. J Neurooncol
. 2019
;144
(3
):553
–62
. .70.
Harder
H
, Cornelissen
JJ
, Van Gool
AR
, Duivenvoorden
HJ
, Eijkenboom
WM
, van den Bent
MJ
. Cognitive functioning and quality of life in long-term adult survivors of bone marrow transplantation
. Cancer
. 2002
;95
(1
):183
–92
. .71.
Harder
H
, Duivenvoorden
HJ
, van Gool
AR
, Cornelissen
JJ
, van den Bent
MJ
. Neurocognitive functions and quality of life in haematological patients receiving haematopoietic stem cell grafts: a one-year follow-up pilot study
. J Clin Exp Neuropsychol
. 2006
;28
(3
):283
–93
. .72.
Abrey
LE
, Yahalom
J
, DeAngelis
LM
. Treatment for primary CNS lymphoma: the next step
. J Clin Oncol
. 2000
;18
(17
):3144
–50
. © 2020 S. Karger AG, Basel
2020
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
